Universität zu Köln

Shah-Hosseini, Kija ORCID: 0000-0001-9616-6942, Mioc, Katharina, Hadler, Meike, Karagiannis, Efstrathios and Moesges, Ralph (2015). Optimum treatment strategies for polyallergic patients - analysis of a large observational trial. Curr. Med. Res. Opin., 31 (12). S. 2249 - 2260. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1473-4877

Full text not available from this repository.

Abstract

Objectives:To document the effectiveness and safety of sublingual allergen immunotherapy (SLIT) with a five-grass pollen tablet (Oralair) and compare different treatment options in a broad, non-selected population of patients in a real-world clinical setting.Research design and methods:This was a 2 year, open, prospective, multicenter, single-arm, non-interventional study. Patients with a history of clinically relevant allergic symptoms caused by grass pollen, confirmed by skin prick testing, received treatment with the five-grass pollen tablet. Concomitant treatment with symptomatic medication and/or additional SLIT or subcutaneous immunotherapy (SCIT) was permitted. Twelve-month data are presented here. Effectiveness was assessed comparing a combined rhinoconjunctivitis (RC) score derived from the severity of rhinitis and conjunctivitis symptoms under treatment with retrospective data of the previous year.Results:A total of 1408 patients participated in the study, of whom 434 were children/adolescents and 962 polyallergic. Compared with the grass pollen season preceding five-grass pollen tablet treatment, a statistically significant reduction of 49.9% was achieved in RC score for the total population (p<0.001), and an improvement in overall health was perceived by 90.9% of patients. The overall population of polyallergic patients derived similar benefits from treatment with the five-grass pollen tablet as monoallergic patients. The percentage reduction in RC score was larger in polyallergic patients taking no additional therapy (60.2%) than in those taking concomitant symptomatic medication (38.1%) or allergen immunotherapy (AIT) (50.8%). Within the last of these groups, RC score improved by 47.6% among patients receiving additional SCIT, versus 54.8% with additional SLIT. Adverse drug reactions, reported in 15.3% of study participants, were mostly local in nature and mild or moderate in intensity.Conclusions:After 1 year of treatment, polyallergic patients responded similarly to the five-grass pollen tablet as monoallergic patients. For polyallergic patients in whom additional treatment was needed, a second SLIT may be more beneficial than a SCIT or symptomatic co-medication.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Shah-Hosseini, Kija UNSPECIFIED orcid.org/0000-0001-9616-6942 UNSPECIFIED Mioc, Katharina UNSPECIFIED UNSPECIFIED UNSPECIFIED Hadler, Meike UNSPECIFIED UNSPECIFIED UNSPECIFIED Karagiannis, Efstrathios UNSPECIFIED UNSPECIFIED UNSPECIFIED Moesges, Ralph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-384370
DOI:	10.1185/03007995.2015.1094653
Journal or Publication Title:	Curr. Med. Res. Opin.
Volume:	31
Number:	12
Page Range:	S. 2249 - 2260
Date:	2015
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1473-4877
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SUBLINGUAL IMMUNOTHERAPY TABLETS; ALLERGEN-SPECIFIC IMMUNOTHERAPY; EFFICACY; RHINITIS; GRASS; SAFETY; ASTHMA; POLYSENSITIZATION; MULTIPLE; IMPACT Multiple languages Medicine, General & Internal; Medicine, Research & Experimental Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/38437